Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
AXDX on Nasdaq
Shares outstanding
27,795,576
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
0
Total reported value
$0
Share change
-325,239
Value change
-$2,082
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Indaba Capital Management, L.P. 9.9% $3,302,114 2,751,762 Indaba Capital Management, L.P. 04 Feb 2025

As of 30 Sep 2025, 0 institutional investors reported holding 0 shares of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX). This represents 0% of the company’s total 27,795,576 outstanding shares.

Institutional Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 0 $0 -$2,082 0
2025 Q2 325,239 $2,082 $0.01 1
2025 Q1 325,239 $227,992 $0.70 1
2024 Q4 325,239 $390,287 $1.20 1
2024 Q3 325,239 $556,158 $0 $1.71 1
2024 Q2 325,239 $380,529 $0 $1.17 1
2024 Q1 325,239 $321,986 -$171,464 $0.99 1
2023 Q4 294,235 $1,153,398 -$24,627 $3.92 2
2023 Q3 292,312 $1,680,790 -$27,247,165 $5.75 2
2023 Q2 22,017,445 $17,831,840 -$1,718,876 $0.81 46
2023 Q1 24,490,500 $17,143,967 -$720,822 $0.70 63
2022 Q4 25,462,485 $17,969,636 -$2,260,786 $0.71 69
2022 Q3 26,398,896 $40,128,620 +$12,883,590 $1.52 71
2022 Q2 18,550,706 $18,407,012 -$4,675,144 $0.99 61
2022 Q1 20,236,639 $29,130,831 -$1,711,961 $1.44 90
2021 Q4 23,236,056 $121,261,081 +$491,919 $5.22 96
2021 Q3 23,529,605 $137,931,831 -$3,022,842 $5.83 103
2021 Q2 24,106,124 $194,252,639 -$4,061,932 $8.06 91
2021 Q1 24,589,192 $204,541,300 -$23,799,929 $8.32 96
2020 Q4 27,689,979 $209,893,010 -$8,354,009 $7.58 110
2020 Q3 27,165,106 $289,588,609 -$2,803,380 $10.66 109
2020 Q2 29,541,054 $447,806,123 +$4,633,079 $15.16 118
2020 Q1 29,163,768 $242,932,782 -$6,110,664 $8.33 100
2019 Q4 30,235,734 $510,962,732 +$12,287,490 $16.90 102
2019 Q3 25,766,429 $478,507,174 +$934,063 $18.57 108
2019 Q2 29,068,241 $665,121,466 +$51,009,611 $22.88 111
2019 Q1 26,950,896 $566,547,380 -$5,993,465 $21.02 108
2018 Q4 27,382,513 $314,946,453 +$10,081,535 $11.50 101
2018 Q3 26,494,703 $607,904,970 +$45,139,765 $22.95 114
2018 Q2 24,484,548 $545,998,652 +$80,316,917 $22.30 112
2018 Q1 20,884,201 $477,195,475 -$142,261 $22.85 113
2017 Q4 20,728,922 $543,155,858 -$30,021,361 $26.20 111
2017 Q3 22,070,068 $495,397,532 +$43,046,118 $22.45 113
2017 Q2 20,241,250 $553,573,286 +$12,755,160 $27.35 114
2017 Q1 20,315,256 $492,364,208 +$161,522,849 $24.20 94
2016 Q4 15,148,969 $314,351,271 +$14,279,372 $20.75 103
2016 Q3 14,391,055 $392,294,474 +$29,290,433 $27.26 98
2016 Q2 13,556,644 $195,816,651 -$4,162,247 $14.39 93
2016 Q1 13,689,300 $196,431,827 -$7,701,440 $14.37 89
2015 Q4 13,599,931 $290,948,310 +$71,230,645 $21.49 93
2015 Q3 10,400,675 $168,280,869 +$261,666 $16.18 87
2015 Q2 9,810,831 $253,209,742 +$36,170,587 $25.81 83
2015 Q1 8,612,876 $193,764,181 +$18,675,960 $22.50 71
2014 Q4 7,807,573 $149,921,645 +$11,782,962 $19.19 75
2014 Q3 5,335,435 $114,593,901 +$11,356,856 $21.48 70
2014 Q2 4,728,085 $122,931,140 -$84,661,047 $26.00 71
2014 Q1 8,850,304 $192,880,456 +$112,546,198 $21.81 55